CANDEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.9 USD | +3.25% |
|
+14.10% | +505.44% |
| May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
| May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 14.00 | 14.00 | 11.50 |
| Spread/Res. | -36.43% | -36.43% | -22.61% |
| Spread/Supp. | +72.15% | +178.12% | +233.33% |
| Support | 5.170 | 3.200 | 2.670 |
Technical Rankings Surperformance
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- CADL Stock
- Charts Candel Therapeutics, Inc.
